CPI-RSV-F Vaccine (BLB-201) for Respiratory Syncytial Virus

"This clinical trial is seeking 30 human participants aged 18-75 with respiratory syncytial virus infections. Essential criteria for females of childbearing potential include having a negative pregnancy test within 24 hours prior to each vaccination, practicing true abstinence or employing an effective form of contraception if in a heterosexual relationship and agreeing not to donate eggs from the time of vaccination until 90 days after it ends. Male candidates must be postpubertal, use condoms during sexual activity with a female partner that are also utilizing primary contraception and refrain from sperm donation throughout the study timeline. All individuals must provide informed consent before participating in any procedures related to this trial; additionally they"

"As this is the initial phase of clinical trials, demonstrating limited data for both safety and efficacy, our team at Power deemed CPI-RSV-F Vaccine (BLB-201) to have a score of 1 out of 3."

"The upper and lower age limit for this trial is 75 years old and 18 years respectively."

"Affirmative. According to clinicaltrials.gov, this research endeavour was initially advertised on July 20th 2022 and most recently updated on August 16th 2022. 30 participants are sought from 2 different locations."

"This clinical trial will assess Solicited Adverse Events (SAEs) over a 29-day span. The secondary objectives include evaluating Serious Adverse Events related to the vaccine, noting new onset chronic medical conditions and monitoring frequencies of special interest adverse events from first dose through completion of the trial which is expected to be roughly 6 months post dosing. Lastly, this study will measure changes in RSV F-specific IgG titers after receiving their initial dosage of CPI-RSV-F."

"Affirmatively, the information posted on clinicaltrials.gov verifies that this research is seeking participants with recruitment starting July 20th 2020 and the latest update occurring August 16th 2022. A total of 30 patients will be admitted at two different medical centres."